Orion - Company Announcement

Orion settles patent dispute over the proprietary drug Precedex®

ORION CORPORATION        STOCK EXCHANGE RELEASE 5 DECEMBER 2013 at 3.00  P.M.
EET


Orion Corporation ("Orion") together with Hospira, Inc. ("Hospira") and Sandoz
Inc. and Sandoz Canada Inc. (hereinafter collectively "Sandoz") have executed a
settlement agreement in the lawsuit filed by Orion and Hospira in the United
States against Sandoz regarding Sandoz's submission of abbreviated new drug
application ("ANDA") for generic version of Orion's Precedex® product. The legal
proceedings, which are currently in the appeal phase, concern Orion's US Patent
No. 4,910,214 and Orion's and Hospira's commonly owned US Patent No. 6,716,867.

Under the terms of the settlement agreement, Sandoz may launch generic version
of Precedex on 26 December 2014, unless certain conditions relating to launch,
if triggered, lead to an earlier Sandoz market entry date.

The other terms and conditions of the settlement agreement are confidential.

In compliance with the applicable U.S. laws, the above agreement will be filed
with the United States Federal Trade Commission and the United States Department
of Justice.



Orion Corporation



 Timo Lappalainen  Olli Huotari
 President and CEO SVP, Corporate Functions





Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1747861]